Comparison of interpatient and intrapatient variability in doxorubicin exposure using a validated limited sampling model in dogs with cancer.

ABSTRACT:

Background

Doxorubicin (DOX) is an anthracycline chemotherapeutic used for many canine malignancies, and its adverse event (AE) profile has been well-described in dogs. A limited sampling (LS) pharmacokinetic model was recently developed in canine patients to predict hematologic exposure to DOX. The primary goal of this study was to evaluate within-patient and between-patient variability in DOX exposure over three consecutive doses using the LS model. A secondary goal was to determine if there is a correlation between DOX exposure and gastrointestinal (GI) AEs utilizing a standardized owner questionnaire.

Methods

We performed a prospective evaluation of DOX exposure in seven tumor-bearing dogs across three cycles of treatment and compared the coefficient of variation (%CV) o

SUBMITTER: Veluvolu SM 

PROVIDER: S-EPMC12504394 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature